Astellas Pharma Inc. (OTCMKTS:ALPMY) Shares Shorted: Short Interest Down 56.7% in October

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 65,845 shares, a decrease of 56.7% from the October 15th total of 151,925 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 143,495 shares, the days-to-cover ratio is presently 0.5 days.

Astellas Pharma Price Performance

OTCMKTS:ALPMY traded up $0.34 during mid-day trading on Friday, reaching $16.84. 274,487 shares of the company were exchanged, compared to its average volume of 103,230. Astellas Pharma has a 12 month low of $12.10 and a 12 month high of $17.35. The company has a fifty day moving average of $15.25 and a 200 day moving average of $14.82. The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The stock has a market cap of $30.48 billion, a PE ratio of 12.35 and a beta of 0.06.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Wednesday, November 4th. The company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.06). Astellas Pharma had a return on equity of 26.13% and a net margin of 16.18%. The company had revenue of $3.98 billion during the quarter, compared to the consensus estimate of $3.79 billion. On average, research analysts anticipate that Astellas Pharma will post 1.40 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

About Astellas Pharma

Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company was formed in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, and is headquartered in Tokyo. Astellas develops treatments across areas including oncology, urology, immunology and women’s health. Its medicines include Xtandi (enzalutamide), used to treat certain forms of prostate cancer, and Prograf (tacrolimus), an immunosuppressant used in organ transplantation.